Lumify for treating eye redness

Ocular redness is a common condition that can be caused by inflammation of almost any part of the eye. With frequent use, non-selective redness relieving eye drops that constrict blood vessels in the eye can result in users developing a tolerance or loss of effectiveness, as well as rebound redness.

 In contrast, low-dose brimonidine, the active ingredient in Lumify, selectively constricts veins in the eye, increasing the availability of oxygen to surrounding tissue, thereby reducing the potential risk of these side effects.

Patients with eye redness and irritation can experience negative social connotations, which may impact daily life, having a drop that reduces redness without the side effects of rebound hyperemia or tachyphylaxis, which may lead to overuse and potential corneal toxicity, Lumify is adequate and accurate for treating the condition without side effects.
          haleplushearty.blogspot.com

Rhopressa for treating glaucoma

Rhopressa (netarsudil ophthalmic solution) 0.02%, is a novel once-daily eye drop for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rhopressa is believed to reduce IOP by increasing the outflow of aqueous humor (the fluid inside the eye) through the trabecular meshwork, the main fluid drain of the eye.

Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. Use one drop in the affected eye(s) once daily in the evening. If a dose is missed, treatment should continue with the next dose in the evening. Avoid allowing the tip of the dropper to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution.

 Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. Rhopressa contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of Rhopressa and may be reinserted 15 minutes following its administration.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes between applications. The most common side effect is eye redness. Other common side effects include corneal verticillata, pain at the instillation site, and conjunctival hemorrhage.
          haleplushearty.blogspot.com